Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants

Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants

Infants infected with HIV-1 perinatally despite single-dose nevirapine progress rapidly. Data on treatment outcome in sub-Saharan African infants exposed to single-dose nevirapine are urgently required. This feasibility study addresses efficacy of infant antiretroviral therapy in this setting. HIV-i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AIDS (London) 2008-07, Vol.22 (11), p.1333-1343
Hauptverfasser: Prendergast, Andrew, Mphatswe, Wendy, Tudor-Williams, Gareth, Rakgotho, Mpho, Pillay, Visva, Thobakgale, Christina, McCarthy, Noel, Morris, Lynn, Walker, Bruce D, Goulder, Philip
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Adult
AIDS/HIV
Anti-HIV Agents - administration & dosage
Anti-HIV Agents - therapeutic use
Antiretroviral Therapy, Highly Active - methods
CD4 Lymphocyte Count
Drug Administration Schedule
Drug Resistance, Viral - genetics
Feasibility Studies
Female
HIV Infections - drug therapy
HIV Infections - immunology
HIV Infections - transmission
HIV Infections - virology
HIV-1 - drug effects
HIV-1 - genetics
Human immunodeficiency virus 1
Humans
Infant, Newborn
Infectious Disease Transmission, Vertical
Male
Mutation
Mycobacterium
Nevirapine - therapeutic use
Patient Compliance
Pilot Projects
Pregnancy
Pregnancy Complications, Infectious
Socioeconomic Factors
Treatment Outcome
Viral Load
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Infants infected with HIV-1 perinatally despite single-dose nevirapine progress rapidly. Data on treatment outcome in sub-Saharan African infants exposed to single-dose nevirapine are urgently required. This feasibility study addresses efficacy of infant antiretroviral therapy in this setting. HIV-infected infants in Durban, South Africa, received randomized immediate or deferred (when CD4 cell count reached
ISSN:0269-9370
1473-5571
DOI:10.1097/QAD.0b013e32830437df